Gilead Sciences Inc. has divulged thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among others.
Biomea Fusion Inc. has described GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer, osteoporosis, systemic lupus erythematosus, immunological and inflammatory disorders.
Medshine Discovery Inc. has identified acrylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists reported to be useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Research at China Hinye Pharmaceutical Co. Ltd. has led to the development of μ-opioid receptor agonists reported to be useful for the treatment of pain.
Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic dermatitis, actinic keratosis and psoriasis.
Nitrogen-containing tricyclic compounds acting as pyruvate dehydrogenase kinase 2 (PDHK2; PDK2) inhibitors have been described in a recent Japan Tobacco Inc. patent. They are reported to be useful for the treatment of diabetes, atherosclerosis, cancer, chronic kidney disease, Alzheimer’s disease, heart failure, pulmonary hypertension and stroke.
RSS